Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK inhibitor-supported immunotherapy rechallenge after resolved irAEs in advanced solid tumors
ChiCTR2500103980Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emaxitinib and tofacitinib in Nonhematologic neoplasms, sponsored by Shanghai Changzheng Hospital. Primary endpoint: Incidence of grade 2 or higher and grade 3 or higher immune-related adverse events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
emaxitinibtofacitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500103980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103980.